C07D 215/233
Only one oxygen atom which is attached in position 4
Official title: only one oxygen atom which is attached in position 4
C07D215/233 (Only one oxygen atom which is attached in position 4) appears on 465 US grants and 469 published applications in this corpus.
Search patents in C07D- Granted patents
- 465
- Published applications
- 469
- Assignees
- 296
- Inventors
- 1,662
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 4 | 0 |
| 1977 | 7 | 0 |
| 1978 | 1 | 0 |
| 1979 | 3 | 0 |
| 1980 | 1 | 0 |
| 1981 | 7 | 0 |
| 1982 | 6 | 0 |
| 1983 | 12 | 0 |
| 1984 | 5 | 0 |
| 1985 | 3 | 0 |
| 1986 | 3 | 0 |
| 1987 | 4 | 0 |
| 1988 | 7 | 0 |
| 1989 | 8 | 0 |
| 1990 | 9 | 0 |
| 1991 | 4 | 0 |
| 1992 | 12 | 0 |
| 1993 | 18 | 0 |
| 1994 | 10 | 0 |
| 1995 | 10 | 0 |
| 1996 | 8 | 0 |
| 1997 | 4 | 0 |
| 1998 | 7 | 0 |
| 1999 | 7 | 0 |
| 2000 | 3 | 0 |
| 2001 | 2 | 0 |
| 2002 | 8 | 14 |
| 2003 | 9 | 14 |
| 2004 | 10 | 23 |
| 2005 | 10 | 13 |
| 2006 | 9 | 24 |
| 2007 | 11 | 20 |
| 2008 | 8 | 14 |
| 2009 | 17 | 24 |
| 2010 | 10 | 25 |
| 2011 | 17 | 15 |
| 2012 | 22 | 18 |
| 2013 | 24 | 27 |
| 2014 | 19 | 32 |
| 2015 | 17 | 17 |
| 2016 | 8 | 18 |
| 2017 | 15 | 17 |
| 2018 | 9 | 16 |
| 2019 | 11 | 13 |
| 2020 | 13 | 17 |
| 2021 | 14 | 26 |
| 2022 | 11 | 12 |
| 2023 | 10 | 28 |
| 2024 | 6 | 18 |
| 2025 | 10 | 13 |
| 2026 | 2 | 11 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Membrane-active anti-bacterial compounds and uses thereof29 Sep 2026US 12,747,213 B2Regents of the University of Minnesota
- TEAD inhibitors and uses thereof16 Jun 2026US 12,655,150 B2Cedilla Therapeutics, Inc.
- Intermediates and synthesis for Endochin-like quinolone compounds30 Dec 2025US 12,509,427 B2Oregon Health & Science University
- Compounds for the treatment of kinase-dependent disorders23 Dec 2025US 12,503,438 B2Exelixis, Inc.
- Heteroaryl compounds for the treatment of pain23 Dec 2025US 12,503,439 B2Vertex Pharmaceuticals Incorporated
- Crystalline forms of 3-(5,7-difluoro-4-oxo-1,4-dihydroquinolin-2-yl)-4-(methylsulfonyl)benzonitrile8 Oct 2026US 2026/0308126 A1
- Heterocyclic derivatives, compositions and uses thereof17 Sep 2026US 2026/0274799 A1Danatlas Pharmaceuticals Co., Ltd.
- Polycyclic thyroid hormone beta receptor agonist and use thereof20 Aug 2026US 2026/0242350 A1Cascade Pharmaceuticals, Inc.
- Compounds and method for treating hiv infection30 Jul 2026US 2026/0216172 A1The United States of America, as represented by the Secretary, Department of Health and Human Servic
- Processes for making endochin-like quinolones from alkyl 3-(3-alkoxyphenyl)amino)-2-(4-(4-alkoxy)phenoxy)phenyl)but-2-enoate23 Jul 2026US 2026/0209161 A1Intervet Inc.
Most cited
By later US patents
- Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase226US 5,480,883 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1996
- Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase209US 5,409,930 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1995
- Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase198US 5,710,158 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1998
- Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase171US 5,646,153 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1997
- Modulators of ATP-binding cassette transporters157US 7,495,103 B2Vertex Pharmaceuticals Incorporated · 2009